Paratek Pharmaceuticals announced that the Company’s independent directors of the Board have appointed Jeffrey Stein, PhD as its first Lead Independent Director, effective December 8, 2022. Dr. Stein was selected unanimously by the independent directors of the Board, in recognition of his extensive leadership experience, in-depth knowledge of Paratek and the business of the anti-infective industry. Having served as a director of Paratek since its emergence as a public company in 2014, Dr. Stein has broad experience.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PRTK:
- Paratek Pharmaceuticals Appoints Jeffrey Stein as Lead Independent Director of the Board
- Paratek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield
- Paratek Pharmaceuticals announces data from pilot efficacy study on NUZYRA
- Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Paratek Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue